Pacira BioSciences, Inc. acquires GQ Bio Therapeutics GmbH

GQ Bio announces that it has been acquired by Pacira.

GQ Bio has been pioneering a high-capacity adenoviral gene therapy vector platform and has a preclinical gene therapy pipeline with disease-modifying potential in prevalent musculoskeletal diseases. This transaction is building on Pacira’s plan to transition into an innovative biopharmaceutical organization. Pacira, who has already been a shareholder in GQ Bio, is acquiring the remaining equity interest of approx. 81% for approx. $32 million, net of working capital and other transaction adjustments

Read more here.

Back